Table 2.
Baseline Biomarker Concentrations in Both Randomized Groups
| Control Group | 95% CI | Intervention Group | 95% CI | P Value | |
|---|---|---|---|---|---|
| NT‐proBNPfv (pg/mL) | 97.5 | 61.1 to 155.7 | 63.9 | 45.1 to 90.5 | 0.138 |
| NT‐proBNPCS (pg/mL) | 144.4 | 87 to 239.8 | 82 | 58.1 to 115.7 | 0.06 |
| NT‐proBNPLA (pg/mL) | 94.3 | 59 to 150.8 | 61.4 | 43 to 87.5 | 0.134 |
| MR‐proANPfv (pmol/L) | 114.6 | 77.9 to 151.3 | 98.4 | 82.8 to 113.9 | 0.342 |
| MR‐proANPCS (pmol/L) | 151.5 | 116.1 to 197.8 | 132.5 | 105.9 to 165.9 | 0.451 |
| MR‐proANPLA (pmol/L) | 100.9 | 79.5 to 128.1 | 95.7 | 79.2 to 115.5 | 0.721 |
| Copeptinfv (pmol/L) | 6.68 | 4.95 to 9.01 | 8.21 | 5.5 to 12.27 | 0.471 |
| CopeptinCS (pmol/L) | 7.19 | 5.38 to 9.62 | 9.05 | 5.86 to 14 | 0.464 |
| CopeptinLA (pmol/L) | 6.71 | 4.85 to 9.28 | 8.03 | 5.33 to 12.1 | 0.721 |
| MR‐proADMfv (nmol/L) | 0.654 | 0.565 to 0.734 | 0.583 | 0.53 to 0.636 | 0.134 |
| MR‐proADMCS (nmol/L) | 0.636 | 0.547 to 0.724 | 0.563 | 0.513 to 0.613 | 0.115 |
| MR‐proADMLA (nmol/L) | 0.577 | 0.508 to 0.645 | 0.544 | 0.495 to 0.593 | 0.414 |
NT‐proBNP, MR‐proANP, and copeptin levels are presented as geometric means with 95% CI. MR‐proADM levels are presented as means with 95% CI. Results from t tests are presented, and P<0.05 is considered statistically significant. CI indicates confidence interval; CS, coronary sinus; fv, femoral vein; LA, left atrium; LAm, left atrium mean pressure; MR‐proADM, midregional portion of proadrenomedullin; MR‐proANP, midregional fragment of the N‐terminal precursor of atrial natriuretic peptide; NT‐proBNP, N‐terminal fragment of prodromal B‐type natriuretic peptide.